The NSM niche was associated with additional difficulties in achieving complete remission after therapy in ALL patients, i.e., the transit of Nestin+ MSCs to a-SMA+ CAFs might correlate with BM fibrosis and poor prognosis in ALL. The gene discussed is NES; the disease is acute lymphoblastic leukemia.